search for




 

Original Article
Characteristic Features of Pneumocystis Pneumonia in Pediatric Acute Lymphoblastic Leukemia
Clin Pediatr Hematol Oncol 2018;25:154-61.
Published online October 31, 2018
© 2018 Korean Society of Pediatric Hematology-Oncology and Korean Society for Pediatric Neuro-Oncology

Hyeon A Kim, M.D.1, Haemin Jang, M.D.1, Yu Kyung Kim, M.D.2, Dongsub Kim, M.D.3 and Ji Yoon Kim, M.D.1

Departments of 1Pediatrics and 2Clinical Pathology, School of Medicine, Kyungpook National University, Daegu, 3Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Correspondence to: Ji Yoon Kim
Department of Pediatric Hematology-Oncology, Kyungpook National University Children’s Hospital, Kyungpook National University Chilgok Hospital, 807 Hoguk-ro, Buk-gu, Daegu 41404, Korea
Tel: +82-53-200-5704
Fax: +82-53-425-6683
E-mail: phojyk@knu.ac.kr
ORCID ID: orcid.org/0000-0002-5577-6629
Received September 16, 2018; Revised September 26, 2018; Accepted October 11, 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background: Pneumocystis is difficult to culture or detect in laboratory environments. Its ecology including the timing and method of transmission as well as environmental sources and communicability remain unclear.
Methods: We retrospectively evaluated the pattern and treatment outcome of Pneumocystis jirovecii pneumonia (PCP) in children with acute lymphoblastic leukemia (ALL) who received chemotherapy.
Results: A total of 56 patients with ALL were evaluated. While on chemotherapy, all patients received PCP prophylaxis. PCP were found in a total of 6 patients, including definite PCP in 2, probable PCP in 2, and possible PCP in 2 patients. There were no significant differences in sex, age group, National Cancer Institute risk group, or pneumocystis prophylaxis type between PCP and non-PCP groups. However, there was a significant statistical difference in the times of ALL diagnosis. Regarding recent chemotherapy at the time of PCP diagnosis, there were one induction, one consolidation, and four maintenance cases. All PCP patients were treated with high-dose sulfamethoxazole (100 mg/kg/day) and trimethoprim (20 mg/kg/day) intravenously. Five patients survived, while one patient with endotracheal mechanical ventilation therapy died due to respiratory failure in spite of aggressive treatment.
Conclusion: Pediatric PCP became extremely rare due to routine prophylaxis in clinical practice of pediatric malignancy. Nevertheless, we analyzed patients with acute lymphoblastic leukemia who had received PCP prophylaxis for 14 years, and analyzed the clustered outbreaks of PCP. It is still important to emphasize the need for prophylaxis and to increase the level of attention and isolation under environmental and personal risk factors.
Keywords:
Acute lymphoblastic leukemia, Chemotherapy, Compliance, Outbreaks, Pneumocystis jirovecii pneumonia, Prophylaxis
References
  1. Clark A, Hemmelgarn T, Danziger-Isakov L, Teusink A. Intravenous pentamidine for Pneumocystis carinii/jiroveci pneumonia prophylaxis in pediatric transplant patients. Pediatr Transplant 2015;19:326-31.
    Pubmed CrossRef
  2. O'Connor D, Bate J, Wade R, et al. Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood 2014;124:1056-61.
    Pubmed CrossRef
  3. Walzer PD. The ecology of pneumocystis: perspectives, personal recollections, and future research opportunities. J Eukaryot Microbiol 2013;60:634-45.
    Pubmed KoreaMed CrossRef
  4. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Health Care Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 2007;35:S65-164.
    Pubmed CrossRef
  5. Roux A, Gonzalez F, Roux M, et al. Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. Med Mal Infect 2014;44:185-98.
    Pubmed CrossRef
  6. Kim KR, Kim JM, Kang JM, Kim YJ. Pneumocystis jirovecii pneumonia in pediatric patients: an analysis of 15 confirmed consecutive cases during 14 years. Korean J Pediatr 2016;59:252-5.
    Pubmed KoreaMed CrossRef
  7. Caselli D, Petris MG, Rondelli R, et al. Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. J Pediatr 2014;164:389-92.e1.
    Pubmed CrossRef
  8. Kim SY, Dabb AA, Glenn DJ, Snyder KM, Chuk MK, Loeb DM. Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients. Pediatr Blood Cancer 2008;50:779-83.
    Pubmed KoreaMed CrossRef
  9. Kim SH, Yoo RN, Sung HS, Lee JN. Clinical characteristics, prognostic factors and influence of prophylaxis in children with pneumocystis jirovecii pneumonia. Pediatr Infect Vaccine 2016;23:31-9.
    CrossRef
  10. Azoulay É, Bergeron A, Chevret S, Bele N, Schlemmer B, Menotti J. Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 2009;135:655-61.
    CrossRef
  11. Grant LR, Hammitt LL, Murdoch DR, O'Brien KL, Scott JA. Procedures for collection of induced sputum specimens from children. Clin Infect Dis 2012;54 Suppl 2:S140-5.
    Pubmed KoreaMed CrossRef
  12. Leigh TR, Collins JV. Detection of Pneumocystis carinii. Lancet 1990;336:1329.
    CrossRef
  13. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
    Pubmed CrossRef
  14. Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia:A Report From Children's Oncology Group Study AALL0232. J Clin Oncol 2016;34:2380-8.
    Pubmed KoreaMed CrossRef
  15. Mitchell HR, Lu X, Myers RM, et al. Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331. Int J Cancer 2016;138:332-9.
    Pubmed KoreaMed CrossRef
  16. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008;111:2548-55.
    Pubmed KoreaMed CrossRef
  17. Matloub Y, Bostrom BC, Hunger SP, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011;118:243-51.
    Pubmed KoreaMed CrossRef
  18. Gajjar A, Ribeiro R, Hancock ML, et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995;86:1292-5.
    Pubmed
  19. Matloub Y, Lindemulder S, Gaynon PS, et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood 2006;108:1165-73.
    Pubmed KoreaMed CrossRef
  20. Vargas SL, Hughes WT, Santolaya ME, et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis 2001;32:855-61.
    Pubmed CrossRef
  21. Navin TR, Rimland D, Lennox JL, et al. Risk factors for communityacquired pneumonia among persons infected with human immunodeficiency virus. J Infect Dis 2000;181:158-64.
    Pubmed CrossRef
  22. Casanova-Cardiel L, Leibowitz MJ. Presence of Pneumocystis carinii DNA in pond water. J Eukaryot Microbiol 1997;44:28s.
    Pubmed CrossRef
  23. Choukri F, Menotti J, Sarfati C, et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis 2010;51:259-65.
    Pubmed CrossRef
  24. Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jir ovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 2014;44:1350-63.
    Pubmed CrossRef
  25. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977;297:1419-26.
    Pubmed CrossRef
  26. Wolff LJ. Supportive care for children with cancer. Guidelines of the Childrens Cancer Study Group. Use of prophylactic antibiotics. Am J Pediatr Hematol Oncol 1984;6:267-76.
    Pubmed CrossRef
  27. Levinsen M, Shabaneh D, Bohnstedt C, et al. Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia. Eur J Haematol 2012;88:78-86.
    Pubmed CrossRef
  28. Poulsen A, Demeny AK, Bang Plum C, Gjerum Nielsen K, Schmiegelow K. Pneumocystis carinii pneumonia during maintenance treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 2001;37:20-3.
    Pubmed CrossRef
  29. Smaldone GC, Vinciguerra C, Marchese J. Detection of inhaled pentamidine in health care workers. N Engl J Med 1991;325:891-2.
    CrossRef
  30. Maschmeyer G, Helweg-Larsen J, Pagano L, et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother 2016;71:2405-13.
    Pubmed CrossRef


October 2018, 25 (2)
Full Text PDF
Citation
Send to a friend
Twitter
Facebook

Cited By Articles
  • CrossRef (0)

Author ORCID Information
  • Ji Yoon Kim